Navigation Links
Statins have neutral effect on risk of cancer

The cholesterol-lowering medications called statins do not appear to reduce the incidence of cancer or cancer deaths, according to a meta-analysis of previous studies in the January 4 issue of JAMA.

Other studies have suggested that statins reduce the risk of developing cancer, the authors provide as background information in the review article. "Statins have been studied in numerous large-scale, randomized, active- or placebo-controlled trials for primary and secondary prevention of coronary artery disease. In these trials, statins reduced the risk of a first myocardial infarction (heart attack) and overall mortality. With long-term follow-up and collection of cancer data in a majority of studies, insight into the risk of cancer among statin-naïve persons and statin users can be derived," the authors write.

C. Michael White, Pharm.D., from the University of Connecticut and Hartford Hospital, Hartford, Conn., and colleagues, conducted a search of the medical literature from 1966 through July 2005 to identify randomized controlled trials of statins. They found 27 articles (n = 86,936 participants) that met their criteria for inclusion, reporting 26 randomized controlled trials of statins with data on either cancer incidence (n = 20 studies) or cancer death (n = 22 studies).

"In our current meta-analysis, statins did not reduce the incidence of cancer or cancer death," the authors report. "No reductions were noted for cancers of the breast, colon, gastrointestinal tract, prostate, respiratory tract, or skin (melanoma) when statins were used." The authors continue, "?the patients in our meta-analysis were primarily treated with simvastatin and pravastatin. As such, we evaluated pravastatin alone and simvastatin alone on cancer incidence and death and found no impact."

"Statins have a neutral effect on cancer and cancer death risks in randomized controlled trials," the authors write in conclusion. "We could find no type of c
'"/>

Source:JAMA and Archives Journals


Page: 1 2

Related biology news :

1. Statins stop hepatitis C virus from replicating
2. Defensins neutralize anthrax toxin
3. Bleach found to neutralize mold allergens
4. Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned
5. Scientific issues associated with carbon-neutral energy sources such as cellulosic ethanol
6. Scientists ID molecular switch in liver that triggers harmful effects of saturated and trans fats
7. Combination therapy boosts effectiveness of telomere-directed cancer cell death
8. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
9. Alcohols effects on gene expression in the central nervous system
10. Boosting HIV screening can increase survival and is cost effective
11. Liposome finding implies electrical effect on cell development
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Statins have neutral effect risk cancer

(Date:6/18/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market announces that its Wocket® smart wallet ... on the Mark", scheduled to air on WABC Radio (am770) ... th . The broadcast air- time for ... 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira will ...
(Date:6/16/2015)... 16, 2015 /CNW Telbec/ - handyem Inc. and ... the incorporation of handyem,s HPC-150 portable flow cytometer ... Mo-POD™. This unprecedented model of mobile laboratory platform ... the Pennsylvania Convention Center, ... th to 18 th 2015.  By ...
(Date:6/15/2015)... 2015 A new report [ ... majority of US consumers using mobile banking applications want their ... fingerprint and voiceprint, instead of having to prove who they ... " Mobile Identity   -   The Fusion of Financial ... now the primary channel used by Gen X and Gen ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4
... primary ingredient of blood clots, creates a fibrous network that ... But beyond this essential work, fibrin can also cause heart ... blood vessels. Fibrin forms when an enzyme removes parts ... into "holes" located on both ends of fibrinogen molecules. Uncovering ...
... release is available in Spanish . ... tubers with red, yellow, orange and purple flesh. This ... scientists in Prosser, Wash., are discovering. Together ... detecting and measuring phytonutrient concentrations in the tubers. Phytonutrients ...
... WASHINGTON, DC May 18, 2010 -- The American ... mBio , a new open access online journal designed ... the journal is on rapid publication of cutting-edge research spanning ... "The microbial world is a highly interconnected one ...
Cached Biology News:New study reveals ways to better inhibit blood clots 2New study reveals ways to better inhibit blood clots 3ASM launches new open access journal 2
(Date:7/3/2015)... 3, 2015 Forskere ... 2015 på  http://www.openinnovationinscience.at om efteruddannelsesprogrammet "Lab ... sted i Wien .  ... internationale forskere og videnskabsmænd foretaget af Ludwig ... udfordringer for sundhedsvidenskaben manglen på incitamenter til ...
(Date:7/2/2015)... , July 2, 2015  Spherix Incorporated (Nasdaq: ... fostering and monetization of intellectual property, today announced a ... Spherix Incorporated v. Verizon Services Corp. et al. , ... for the Eastern District of Virginia ... 1, 2015 interpreting certain key claims in favor of ...
(Date:7/2/2015)... ... 2015 , ... In’Tech Medical SAS ( http://www.intech-medical.com ), a ... the acquisition of Turner Medical, Inc ., thus becoming a global leader ... Spine Industry. The acquisition of Turner Medical ideally supplements In’Tech Medical’s product offering, ...
(Date:7/1/2015)... , July 1, 2015   Decision Resources ... cited advantages of Otezla are its oral administration, ... as reported by surveyed rheumatologists. Otezla was the ... the treatment of active psoriatic arthritis in ... standard of care includes conventional oral treatments including ...
Breaking Biology Technology:Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3
... Cell Therapeutics, Inc. (the "Company" or "CTI") (Nasdaq and ... its "Modified Dutch Auction" tender offer to a fixed price ... million outstanding principal amount of five series of its convertible ... offer for a combined aggregate principal amount of Notes, the ...
... , NEW YORK, June 2 Cynvec LLC, a ... therapies that harness the apoptotic ability of the sindbis ... Chief Executive Officer, will make a presentation titled "Cynvec: ... 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical ...
... Inc. (Nasdaq: AMLN ) today announced that ... the Company,s Annual Meeting of Stockholders held May 27, ... The preliminary tabulation indicates that shareholders voted to ... Board of Directors - Adrian Adams, Steven R. Altman, ...
Cached Biology Technology:Cell Therapeutics Amends and Restates Its 'Modified Dutch Auction' Tender Offer to a Fixed Price Tender Offer for Any and All of Its $118.9 Million Outstanding Convertible Notes 2Cell Therapeutics Amends and Restates Its 'Modified Dutch Auction' Tender Offer to a Fixed Price Tender Offer for Any and All of Its $118.9 Million Outstanding Convertible Notes 3Cell Therapeutics Amends and Restates Its 'Modified Dutch Auction' Tender Offer to a Fixed Price Tender Offer for Any and All of Its $118.9 Million Outstanding Convertible Notes 4Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry 2Amylin Announces Preliminary Tabulation of Annual Meeting Results 2Amylin Announces Preliminary Tabulation of Annual Meeting Results 3
... kit for 25 chips provides the chips ... analysis (at nanogram levels) with the Experion ... RNA StdSens microfluidic chips, 2 x 1,250 ... RNA StdSens stain, 2 x 20 microliters ...
...
... is a full featured, two laser, six detector ... Cytometer, CFlow Software, and a PC for operation ... all the capabilities of the best selling flow ... C6 Flow Cytometer System has six detectors to ...
Fingerprinting II Basic software is used for analyzing fingerprint sample types (electrophoretic gels, HPLC and other chromatographic patterns, spectrophotometric and densitometric curves)....
Biology Products: